Kevin N Dalby

List of Publications by Year
in descending order

148 papers	9,357 citations	94269 37 h-index	40881 93 g-index
154 all docs	154 docs citations	154 times ranked	19546 citing authors

#	Article	IF	Citations
1	Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment. Journal of the National Cancer Institute, 2022, 114, 97-108.	3.0	15
2	The Two Non-Visual Arrestins Engage ERK2 Differently. Journal of Molecular Biology, 2022, 434, 167465.	2.0	10
3	Droplet-based screening of phosphate transfer catalysis reveals how epistasis shapes MAP kinase interactions with substrates. Nature Communications, 2022, 13, 844.	5.8	10
4	Multiplexing the Quantitation of MAP Kinase Activities Using Differential Sensing. Journal of the American Chemical Society, 2022, 144, 4017-4025.	6.6	12
5	Discovery of an Effective Small-Molecule Allosteric Inhibitor of New Delhi Metallo-Î²-lactamase (NDM). ACS Infectious Diseases, 2022, 8, 811-824.	1.8	4
6	Biomechanical Dependence of SARS-CoV-2 Infections. ACS Applied Bio Materials, 2022, 5, 2307-2315.	2.3	1
7	Development of cellâ€based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNAâ€PKcs and OCT4â€“MK2 interactions. Biotechnology and Bioengineering, 2021, 118, 1987-2000.	1.7	2
8	A collagen glucosyltransferase drives lung adenocarcinoma progression in mice. Communications Biology, 2021, 4, 482.	2.0	16
9	Structural dynamics of the complex of calmodulin with a minimal functional construct of eukaryotic elongation factor 2 kinase and the role of Thr348 autophosphorylation. Protein Science, 2021, 30, 1221-1234.	3.1	8
10	Luminescence Energy Transferâ€“Based Screening and Target Engagement Approaches for Chemical Biology and Drug Discovery. SLAS Discovery, 2021, 26, 984-994.	1.4	9
11	Development of 2â€²-aminospiro [pyrano[3,2â€“c]quinoline]-3â€²-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation. Bioorganic Chemistry, 2021, 116, 105344.	2.0	14
12	Rapid characterization of spike variants via mammalian cell surface display. Molecular Cell, 2021, 81, 5099-5111.e8.	4.5	32
13	NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth. European Journal of Medicinal Chemistry, 2020, 186, 111885.	2.6	30
14	Quantification of ERK Kinase Activity in Biological Samples Using Differential Sensing. ACS Chemical Biology, 2020, 15, 83-92.	1.6	12
15	A Robust and Cost-Effective Luminescent-Based High-Throughput Assay for Fructose-1,6-Bisphosphate Aldolase A. SLAS Discovery, 2020, 25, 1038-1046.	1.4	1
16	A â€˜light-upâ€™ intercalator displacement assay for detection of triplex DNA stabilizers. Chemical Communications, 2020, 56, 1996-1999.	2.2	3
17	JNK Signaling in Stem Cell Self-Renewal and Differentiation. International Journal of Molecular Sciences, 2020, 21, 2613.	1.8	50
18	Structural Evaluation of Protein/Metal Complexes via Native Electrospray Ultraviolet Photodissociation Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2020, 31, 1140-1150.	1.2	16

#	Article	IF	Citations
19	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Scientific Reports, 2020, 10, 8537.	1.6	28
20	A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition. , 2020, , 109-139.		0
21	Arrestin-3 interaction with maternal embryonic leucine-zipper kinase. Cellular Signalling, 2019, 63, 109366.	1.7	12
22	The role of calcium in the interaction between calmodulin and a minimal functional construct of eukaryotic elongation factor 2 kinase. Protein Science, 2019, 28, 2089-2098.	3.1	8
23	Computational and Experimental Studies of Inhibitor Design for Aldolase A. Journal of Physical Chemistry B, 2019, 123, 6034-6041.	1.2	9
24	Targeting ERK beyond the boundaries of the kinase active site in melanoma. Molecular Carcinogenesis, 2019, 58, 1551-1570.	1.3	26
25	JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. ACS Chemical Biology, 2019, 14, 1426-1435.	1.6	12
26	Computational insights into the binding of IN17 inhibitors to MELK. Journal of Molecular Modeling, 2019, 25, 151.	0.8	5
27	Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition. Journal of Molecular Biology, 2019, 431, 2700-2717.	2.0	8
28	Developing Colorimetric and Luminescence-Based High-Throughput Screening Platforms for Monitoring the GTPase Activity of Ferrous Iron Transport Protein B (FeoB). SLAS Discovery, 2019, 24, 597-605.	1.4	8
29	A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. ACS Chemical Biology, 2019, 14, 1183-1194.	1.6	25
30	A tunable assay for modulators of genome-destabilizing DNA structures. Nucleic Acids Research, 2019, 47, e73-e73.	6.5	7
31	Design, synthesis, and DNA interaction studies of furo-imidazo[3.3.3]propellane derivatives: Potential anticancer agents. Bioorganic Chemistry, 2019, 85, 585-599.	2.0	13
32	Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nature Communications, 2019, 10, 5232.	5.8	17
33	Cover Image, Volume 58, Issue 9. Molecular Carcinogenesis, 2019, 58, i.	1.3	0
34	Development of a High-Throughput Lysyl Hydroxylase (LH) Assay and Identification of Small-Molecule Inhibitors against LH2. SLAS Discovery, 2019, 24, 484-491.	1.4	19
35	Arrestin-3 scaffolding of the JNK3 cascade suggests a mechanism for signal amplification. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 810-815.	3.3	34
36	Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma. Bioorganic Chemistry, 2019, 82, 290-305.	2.0	35

#	Article	IF	Citations
37	Development of a cost effective and robust AlphaScreen^{Â®} platform for HTS application. BioTechniques, 2018, 64, 181-183.	0.8	4
38	Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nature Communications, 2018, 9, 512.	5.8	34
39	A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase. SLAS Discovery, 2018, 23, 1-10.	1.4	6
40	Elucidating the Phosphate Binding Mode of Phosphate-Binding Protein: The Critical Effect of Buffer Solution. Journal of Physical Chemistry B, 2018, 122, 6371-6376.	1.2	20
41	Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca2+-Calmodulin. Journal of Molecular Biology, 2018, 430, 2802-2821.	2.0	15
42	A scalable lysyl hydroxylase 2 expression system and luciferase-based enzymatic activity assay. Archives of Biochemistry and Biophysics, 2017, 618, 45-51.	1.4	13
43	Tinkerâ€OpenMM: Absolute and relative alchemical free energies using AMOEBA on GPUs. Journal of Computational Chemistry, 2017, 38, 2047-2055.	1.5	89
44	Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. Bioorganic and Medicinal Chemistry, 2017, 25, 2609-2616.	1.4	26
45	c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene, 2017, 36, 2599-2608.	2.6	70
46	Signal Integration at Elongation Factor 2 Kinase. Journal of Biological Chemistry, 2017, 292, 2032-2045.	1.6	15
47	Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations. Bioorganic Chemistry, 2017, 75, 242-259.	2.0	41
48	Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. ACS Medicinal Chemistry Letters, 2017, 8, 1072-1076.	1.3	21
49	Local destabilization, rigid body, and fuzzy docking facilitate the phosphorylation of the transcription factor Ets-1 by the mitogen-activated protein kinase ERK2. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6287-E6296.	3.3	22
50	MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opinion on Therapeutic Targets, 2017, 21, 849-859.	1.5	43
51	Optimization of a Luminescence-Based High-Throughput Screening Assay for Detecting Apyrase Activity. SLAS Discovery, 2017, 22, 94-101.	1.4	4
52	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget, 2017, 8, 104894-104912.	0.8	28
53	Structure of the C-Terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2 Kinase. Biochemistry, 2016, 55, 5377-5386.	1.2	4
54	Structural Basis for the Recognition of Eukaryotic Elongation Factor 2 Kinase by Calmodulin. Structure, 2016, 24, 1441-1451.	1.6	19

#	Article	IF	Citations
55	193 nm Ultraviolet Photodissociation Mass Spectrometry for Phosphopeptide Characterization in the Positive and Negative Ion Modes. Journal of Proteome Research, 2016, 15, 2739-2748.	1.8	40
56	Peptide mini-scaffold facilitates JNK3 activation in cells. Scientific Reports, 2016, 6, 21025.	1.6	50
57	Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1Î± Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. Cancer Research, 2016, 76, 4259-4269.	0.4	59
58	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
59	Application of Eukaryotic Elongation Factor-2 Kinase (eEF-2K) for Cancer Therapy: Expression, Purification, and High-Throughput Inhibitor Screening. Methods in Molecular Biology, 2016, 1360, 19-33.	0.4	3
60	Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSAâ^'/lo castration-resistant cells. Oncotarget, 2016, 7, 14220-14240.	0.8	17
61	Structural and Dynamic Features of F-recruitment Site Driven Substrate Phosphorylation by ERK2. Scientific Reports, 2015, 5, 11127.	1.6	19
62	Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis. Frontiers in Molecular Biosciences, 2015, 2, 9.	1.6	15
63	Overexpression of GRK6 rescues l-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats. Experimental Neurology, 2015, 266, 42-54.	2.0	17
64	Arrestinâ€3â€Dependent Activation of câ€Jun Nâ€Terminal Kinases (JNKs). Current Protocols in Pharmacology, 2015, 68, 2.12.1-2.12.26.	4.0	11
65	Mechanistic studies on covalent assemblies of metal-mediated hemi-aminal ethers. Chemical Science, 2015, 6, 158-164.	3.7	26
66	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Molecular Cancer Therapeutics, 2015, 14, 2773-2781.	1.9	61
67	Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Medicinal Chemistry Letters, 2015, 6, 47-52.	1.3	14
68	Targeting the transient receptor potentialâ€melastatinâ€like 7 (Trpm7) kinase domain with the first inhibitor, inhibited breast cancer cell migration, invasion and tumor metastasis.. FASEB Journal, 2015, 29, 1021.9.	0.2	0
69	The Molecular Mechanism of Eukaryotic Elongation Factor 2 Kinase Activation. Journal of Biological Chemistry, 2014, 289, 23901-23916.	1.6	32
70	High-Throughput Screens for eEF-2 Kinase. Journal of Biomolecular Screening, 2014, 19, 445-452.	2.6	24
71	Reversible Covalent Inhibition of eEFâ€2K by Carbonitriles. ChemBioChem, 2014, 15, 2435-2442.	1.3	23
72	Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 4910-4916.	1.4	55

#	Article	IF	Citations
73	Identification and Validation of Novel PERK Inhibitors. Journal of Chemical Information and Modeling, 2014, 54, 1467-1475.	2.5	12
74	Propyphenazone-Based Analogues as Prodrugs and Selective Cyclooxygenase-2 Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 983-988.	1.3	12
75	Modeling Organochlorine Compounds and the Ïƒ-Hole Effect Using a Polarizable Multipole Force Field. Journal of Physical Chemistry B, 2014, 118, 6456-6465.	1.2	69
76	Differential Sensing of MAP Kinases Using SOXâ€Peptides. Angewandte Chemie - International Edition, 2014, 53, 14064-14068.	7.2	37
77	In-Situ Generation of Differential Sensors that Fingerprint Kinases and the Cellular Response to Their Expression. Journal of the American Chemical Society, 2013, 135, 14814-14820.	6.6	69
78	Construction of human activityâ€based phosphorylation networks. Molecular Systems Biology, 2013, 9, 655.	3.2	153
79	A Fluorescenceâ€Based Assay for p38Îł Recruitment Site Binders: Identification of Rooperol as a Novel p38Îł Kinase Inhibitor. ChemBioChem, 2013, 14, 66-71.	1.3	13
80	Elucidating binding modes of zuonin A enantiomers to JNK1 via in silico methods. Journal of Molecular Graphics and Modelling, 2013, 45, 38-44.	1.3	2
81	High-throughput Database Search and Large-scale Negative Polarity Liquid Chromatographyâ€“Tandem Mass Spectrometry with Ultraviolet Photodissociation for Complex Proteomic Samples. Molecular and Cellular Proteomics, 2013, 12, 2604-2614.	2.5	33
82	Arrestin-3 Binds c-Jun N-terminal Kinase 1 (JNK1) and JNK2 and Facilitates the Activation of These Ubiquitous JNK Isoforms in Cells via Scaffolding. Journal of Biological Chemistry, 2013, 288, 37332-37342.	1.6	62
83	JNK3 Enzyme Binding to Arrestin-3 Differentially Affects the Recruitment of Upstream Mitogen-activated Protein (MAP) Kinase Kinases. Journal of Biological Chemistry, 2013, 288, 28535-28547.	1.6	48
84	BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. ELife, 2013, 2, e00969.	2.8	67
85	Evidence of the Regulation of JNK2 through Oligomerization. FASEB Journal, 2013, 27, 789.22.	0.2	0
86	JNK3 binding to arrestinâ€3 differentially affects recruitment of upstream MAP kinase kinases. FASEB Journal, 2013, 27, 1042.4.	0.2	0
87	Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases. Current Pharmaceutical Design, 2012, 18, 1173-1185.	0.9	19
88	Manipulating JNK Signaling with (â^')-Zuonin A. ACS Chemical Biology, 2012, 7, 1873-1883.	1.6	20
89	Corrigendum to â€œPurification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coliâ€•[Protein Expression and Purification 79 (2011) 237â€“244]. Protein Expression and Purification, 2012, 85, 250.	0.6	0
90	Calcium/Calmodulin Stimulates the Autophosphorylation of Elongation Factor 2 Kinase on Thr-348 and Ser-500 To Regulate Its Activity and Calcium Dependence. Biochemistry, 2012, 51, 2232-2245.	1.2	56

#	Article	IF	Citations
91	From in Silico Discovery to Intracellular Activity: Targeting JNKâ€“Protein Interactions with Small Molecules. ACS Medicinal Chemistry Letters, 2012, 3, 721-725.	1.3	25
92	Docking Interactions of Hematopoietic Tyrosine Phosphatase with MAP Kinases ERK2 and p38Î±. Biochemistry, 2012, 51, 8047-8049.	1.2	20
93	Induction of Autophagy by Polyphenolic Compounds in Cancer: A Novel Strategy to induce cell death and to Treat Cancer. , 2012, , 237-261.		1
94	Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer. PLoS ONE, 2012, 7, e41171.	1.1	95
95	Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact. Biochemistry, 2012, 51, 2100-2112.	1.2	52
96	Chargeâ€Siteâ€Dependent Dissociation of Hydrogenâ€Rich Radical Peptide Cations upon Vacuum UV Photoexcitation. Chemistry - A European Journal, 2012, 18, 5374-5383.	1.7	19
97	Assignment of Backbone Resonances in a Eukaryotic Protein Kinase â€“ ERK2 as a Representative Example. Methods in Molecular Biology, 2012, 831, 359-368.	0.4	10
98	Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases. Current Drug Metabolism, 2012, 18, 1173-1185.	0.7	1
99	Examining Docking Interactions on ERK2 with Modular Peptide Substrates. Biochemistry, 2011, 50, 9500-9510.	1.2	34
100	Nonvisual Arrestins Function as Simple Scaffolds Assembling the MKK4â€“JNK3Î±2 Signaling Complex. Biochemistry, 2011, 50, 10520-10529.	1.2	61
101	Development of JNK2-Selective Peptide Inhibitors That Inhibit Breast Cancer Cell Migration. ACS Chemical Biology, 2011, 6, 658-666.	1.6	44
102	Activated ERK2 Is a Monomer in Vitro with or without Divalent Cations and When Complexed to the Cytoplasmic Scaffold PEA-15. Biochemistry, 2011, 50, 4568-4578.	1.2	38
103	Solution NMR Insights into Docking Interactions Involving Inactive ERK2. Biochemistry, 2011, 50, 3660-3672.	1.2	39
104	Understanding the Specificity of a Docking Interaction between JNK1 and the Scaffolding Protein JIP1. Journal of Physical Chemistry B, 2011, 115, 1491-1502.	1.2	34
105	Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli. Protein Expression and Purification, 2011, 79, 237-244.	0.6	25
106	The Effect of Arrestin Conformation on the Recruitment of c-Raf1, MEK1, and ERK1/2 Activation. PLoS ONE, 2011, 6, e28723.	1.1	87
107	Virtual screening using molecular simulations. Proteins: Structure, Function and Bioinformatics, 2011, 79, 1940-1951.	1.5	171
108	193â€nm photodissociation of singly and multiply charged peptide anions for acidic proteome characterization. Proteomics, 2011, 11, 1329-1334.	1.3	70

#	Article	IF	Citations
109	A Model of a MAPKâ€¢Substrate Complex in an Active Conformation: A Computational and Experimental Approach. PLoS ONE, 2011, 6, e18594.	1.1	20
110	Conformational preference of ChaK1 binding peptides: a molecular dynamics study. PMC Biophysics, 2010, 3, 2.	2.2	2
111	Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer. Autophagy, 2010, 6, 322-329.	4.3	394
112	Fluorescent Peptide Assays for Protein Kinases. Current Protocols in Molecular Biology, 2010, 91, Unit 18.17.	2.9	7
113	Phosphorylation of the Transcription Factor Ets-1 by ERK2: Rapid Dissociation of ADP and Phospho-Ets-1. Biochemistry, 2010, 49, 3619-3630.	1.2	26
114	Synthesis and biological evaluation of p38Î± kinase-targeting dialkynylimidazoles. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6293-6297.	1.0	23
115	Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 276-283.	1.3	53
116	Substrate Discrimination among Mitogen-activated Protein Kinases through Distinct Docking Sequence Motifs. Journal of Biological Chemistry, 2008, 283, 19511-19520.	1.6	130
117	The expression and purification of the N-terminal activation domain of the transcription factor c-Myc: A model substrate for exploring ERK2 docking interactions. Protein Expression and Purification, 2007, 53, 80-86.	0.6	3
118	Regulation of protein phosphorylation within the MKK1â€“ERK2 complex by MP1 and the MP1â€¢P14 heterodimer. Archives of Biochemistry and Biophysics, 2007, 460, 85-91.	1.4	5
119	Expanding the Repertoire of an ERK2 Recruitment Site:â€‰ Cysteine Footprinting Identifies the D-Recruitment Site as a Mediator of Ets-1 Binding. Biochemistry, 2007, 46, 9174-9186.	1.2	35
120	The Anti-Apoptotic Protein PEA-15 Is a Tight Binding Inhibitor of ERK1 and ERK2, Which Blocks Docking Interactions at the D-Recruitment Site. Biochemistry, 2007, 46, 9187-9198.	1.2	52
121	Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. Journal of Neurochemistry, 2007, 102, 699-711.	2.1	72
122	Properties and Regulation of a Transiently Assembled ERK2Â·Ets-1 Signaling Complexâ€. Biochemistry, 2006, 45, 13719-13733.	1.2	43
123	Quantifying ERK2â€“protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 316-323.	1.1	27
124	Following in vitro activation of mitogen-activated protein kinases by mass spectrometry and tryptic peptide analysis: purifying fully activated p38 mitogen-activated protein kinase Î±. Analytical Biochemistry, 2005, 336, 1-10.	1.1	11
125	Kinetic mechanism for p38 MAP kinase alpha. A partial rapid-equilibrium random-order ternary-complex mechanism for the phosphorylation of a protein substrate. FEBS Journal, 2005, 272, 4631-4645.	2.2	21
126	Reaction Mechanisms. Part 2. Polar Reactions. ChemInform, 2005, 36, no.	0.1	0

#	Article	IF	Citations
127	11ÂÂReaction mechanisms : Part (ii) Polar reactions. Annual Reports on the Progress of Chemistry Section B, 2005, 101, 264.	0.8	0
128	Proximity-Induced Catalysis by the Protein Kinase ERK2. Journal of the American Chemical Society, 2005, 127, 10494-10495.	6.6	45
129	Phage display identifies novel peptides that bind extracellular-regulated protein kinase 2 to compete with transcription factor binding. Journal of Physical Organic Chemistry, 2004, 17, 461-471.	0.9	0
130	Reaction Mechanisms. Part 2. Polar Reactions. ChemInform, 2004, 35, no.	0.1	0
131	A kinetic approach towards understanding substrate interactions and the catalytic mechanism of the serine/threonine protein kinase ERK2: identifying a potential regulatory role for divalent magnesium. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 81-87.	1.1	11
132	12ÂÂReaction mechanisms : Part (ii) Polar reactions. Annual Reports on the Progress of Chemistry Section B, 2004, 100, 311-333.	0.8	1
133	Conserved Elements of the Cytochrome P-450 Superfamily Found in Monoamine Oxidase B. NeuroToxicology, 2004, 25, 73-78.	1.4	0
134	Reaction Mechanisms. Part 1. Polar Reactions. ChemInform, 2003, 34, no.	0.1	0
135	Physiological Concentrations of Divalent Magnesium Ion Activate the Serine/Threonine Specific Protein Kinase ERK2â€. Biochemistry, 2003, 42, 2960-2970.	1.2	48
136	Two Rate-Limiting Steps in the Kinetic Mechanism of the Serine/Threonine Specific Protein Kinase ERK2:Â A Case of Fast Phosphorylation Followed by Fast Product Releaseâ€. Biochemistry, 2003, 42, 12273-12286.	1.2	37
137	10â€ƒâ€ƒReaction mechanisms : Part (ii) Polar reactions. Annual Reports on the Progress of Chemistry Section B, 2003, 99, 351.	0.8	1
138	Transient Protein-Protein Interactions and a Random-ordered Kinetic Mechanism for the Phosphorylation of a Transcription Factor by Extracellular-regulated Protein Kinase 2. Journal of Biological Chemistry, 2002, 277, 12532-12540.	1.6	41
139	Toward a Stable Hydroxyphosphorane. Organic Letters, 2002, 4, 201-203.	2.4	12
140	6â€ƒâ€ƒReaction mechanisms : Part (i) Polar reactions. Annual Reports on the Progress of Chemistry Section B, 2002, 98, 253-291.	0.8	2
141	Purification of a Model Substrate for Transcription Factor Phosphorylation by ERK2. Protein Expression and Purification, 2001, 23, 191-197.	0.6	21
142	Mechanism of catalysis of the hydrolysis of a formamidinium compound. Perkin Transactions II RSC, 2001, , 1961-1967.	1.1	1
143	The Kinetic Mechanism of the Dual Phosphorylation of the ATF2 Transcription Factor by p38 Mitogen-activated Protein (MAP) Kinase Î±. Journal of Biological Chemistry, 2001, 276, 5676-5684.	1.6	67
144	Identification of Regulatory Phosphorylation Sites in Mitogen-activated Protein Kinase (MAPK)-activated Protein Kinase-1a/p90 That Are Inducible by MAPK. Journal of Biological Chemistry, 1998, 273, 1496-1505.	1.6	333

#	Article	IF	Citations
145	Lifetimes of Imidinium Ions in Aqueous Solution. Journal of the American Chemical Society, 1997, 119, 7271-7280.	6.6	11
146	Comparison of the specificities of p70 S6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 S6 kinase: the N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide phosphorylation. FEBS Letters, 1995, 375, 289-293.	1.3	114
147	Models for nuclease catalysis: mechanisms for general acid catalysis of the rapid intramolecular displacement of methoxide from a phosphate diester. Journal of the Chemical Society Perkin Transactions II, 1993, , 1269.	0.9	24
148	Electrostatic catalysis of the hydrolysis of a phosphate diester in water. Journal of the Chemical Society Chemical Communications, 1992, , 1770.	2.0	5